ERBB2 and gastric cancer: In pre-clinical models of GC, treatment with CAR-T cells specific for the HER2 oncoprotein as well as the use of a bifunctional αHER2(Ag1)/CD3 (Ag2) RNA-engineered CAR-T-like human T cells, induced a marked regression of the tumor and prolonged the survival of tumor-bearing mice [67,68].